Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

Characteristics of IEF Patterns and SDS-PAGE Results of Korean EPO Biosimilars

  • Kang, Min-Jung (Integrated Omics Center, Korea Institute of Science and Technology) ;
  • Shin, Sang-Mi (Doping Control Center, Korea Institute of Science and Technology) ;
  • Yoo, Hey-Hyun (Department of Pharmacy, College of Pharmacy, Hanyang University) ;
  • Kwon, Oh-Seung (Doping Control Center, Korea Institute of Science and Technology) ;
  • Jin, Chang-Bae (Integrated Omics Center, Korea Institute of Science and Technology)
  • Received : 2010.07.01
  • Accepted : 2010.07.12
  • Published : 2010.09.20
Download PDF
⟨ Previous Next ⟩

Abstract

Erythropoietin (EPO) is mainly produced in kidney and stimulates erythropoiesis. The use of recombinant EPOs for doping is prohibited because of its performance enhancing effect. This study investigated whether biosimilar EPOs could be differentiated from endogenous one by iso-electro-focusing plus double blotting and SDS-PAGE for antidoping analysis. The established method was validated with positive control urine. The band patterns were reproducible and meet the criteria, which was made by world anti doping agency (WADA). Isoelectric focusing was conducted in pH range 2 to 6. Recormon (La Roche), Aropotin (Kunwha), Epokine (CJ Pharm Co.), Eporon (Dong-A), Espogen (LG Life Sciences), and Dynepo (Shire Pharmaceuticals) were detected in basic region. All biosimilars showed discriminative isoelectric profiles from endogenous EPO profiles, but they showed different band patterns with the reference one except Epokine (CJ Pharm Co.). Next, SDS-PAGE of biosimilar EPOs resulted in different molecular weight patterns which were distributed higher than endogenous EPO. Commercial immune assay kit as an immune affinity purification tool and immobilized antibody coated magnetic bead were tested for the purification and concentration of EPO from urinary matrix. The antibody-coated magnetic bead gave better purification yield. The IEF plus double blotting and SDS-PAGE with immunoaffinity purification method established can be used to discriminate biosimilar EPOs from endogenous EPO.

Keywords

References

  1. Miyake, T.; Kung, C. K-H.; Goldwasser, E. Journal of Biological Chemistry 1977, 252, 5558.
  2. Faulds, D.; Sorkin, E. M. Drugs 1989, 38, 863. https://doi.org/10.2165/00003495-198938060-00004
  3. Lasne, F.; Ceaurriz, J. D. Nature 2000, 405, 635.
  4. Lasne, F. Journal of Immunological Methods 2001, 253, 125. https://doi.org/10.1016/S0022-1759(01)00355-6
  5. Lasne, F.; Martin, L.; Crepin, N.; Ceauriz, J. D. Analytical Biochemistry2002, 311, 119. https://doi.org/10.1016/S0003-2697(02)00407-4
  6. Lasne, F. Journal of Immunological Methods 2003, 276, 223. https://doi.org/10.1016/S0022-1759(03)00065-6
  7. Parisotto, R.; Gore, C. J.; Emslie, K. R.; Ashenden, M. J.; Brugnara,C.; Howe, C.; Martin, D. T.; Trout, G. J.; Hahn, A. G. Haematologica2000, 85, 564.
  8. Breidbach, A.; Catlin, D. H.; Green, G. A.; Tregub, I.; Truong, H.;Gorzek, J. Clinical Chemistry 2003, 49, 901. https://doi.org/10.1373/49.6.901
  9. Pascual, J. A.; Belalcazar, V.; debolos, C.; Gutierrez, R.; Llop, E.;Segura, J. Ther Drug Monit 2004, 26, 175. https://doi.org/10.1097/00007691-200404000-00016
  10. Kochendoefer, G. G. et al. Science 2003, 299, 884. https://doi.org/10.1126/science.1079085
  11. Khan, A.; Grinyer, J.; Truong, S. T.; Breen, J.; Packer, N. H. Clinica Chimica Acta 2005, 358, 119. https://doi.org/10.1016/j.cccn.2005.03.013
  12. Franke, W. W.; Heid, H. Clinica Chimica Acta 2006, 373, 189. https://doi.org/10.1016/j.cca.2006.05.024
  13. Rabin, O. P.; Lasne, F.; Pascual, J. A.; Saugy, M.; Delbeke, F. J. ClinicaChimica Acta 2006, 373, 186. https://doi.org/10.1016/j.cca.2006.03.020
  14. Reichel, C.; Kulovics, R.; Jordan, V.; Watzinger, M.; Geisendorfer,T. Drug Testing and Analysis 2009, 1, 43. https://doi.org/10.1002/dta.10
  15. Park, S. S.; Park, J.; Ko, J.; Chen, L.; Meriage, D.; Crouge-Zeineddini,J.; Wong, W.; Kerwin, B. A. Journal of Pharmaceutical Sciences 2009, 98, 1688. https://doi.org/10.1002/jps.21546
  16. Loennberg, M.; Drevin, M.; Carlsson, J. Journal of Immunological Methods 2008, 339, 236. https://doi.org/10.1016/j.jim.2008.09.022
  17. Desharnais, P.; Ayotte, C. In Recent Advances in Doping Analysis;Sportverlag Strauss: Colone, 2007; p 303.
  18. Kohler, M.; Ayotte, C.; Desharnais, P.; Flenker, U.; Luedke, S.;Thevis, M.; Voelker-Schaenzer, E.; Schaenzer, W. Int. J. Sports Med. 2008, 29, 1. https://doi.org/10.1055/s-2007-989369
  19. World Anti-doping Agency; http://www.wada-ama.org.

Cited by

  1. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin vol.5, pp.5, 2013, https://doi.org/10.4155/bio.13.9
  2. Structure-based comprehensive identification of erythropoiesis-stimulating agents and their biosimilars vol.32, pp.2, 2014, https://doi.org/10.1007/s11419-014-0225-x
  3. Surface-enhanced Raman probe for rapid nanoextraction and detection of erythropoietin in urine vol.408, pp.29, 2016, https://doi.org/10.1007/s00216-016-9966-1
  4. -terminal arginine residues vol.8, pp.11-12, 2016, https://doi.org/10.1002/dta.2102